In an unexpected development, an elderly woman with advanced Alzheimer’s experienced a notable reversal of symptoms following use of psilocybin-containing mushrooms, opening a window into possible new approaches for brain health.
- Woman with advanced Alzheimer’s regained speech and mobility after psilocybin use
- Effects lasted days to weeks, with improved recognition and independence
- Findings reflect brain plasticity but require larger clinical studies
What happened
A woman in her 80s with severe Alzheimer’s disease, who had been declining for over a decade and largely nonverbal for five years, was given psilocybin-containing mushrooms under supervision. After the initial 5g dose, she entered a sleep-like state but awakened within 19 hours to begin speaking spontaneously and recalling memories. Over the next weeks, caregivers saw improvements in her alertness, ability to walk and dress independently, and return of urinary continence.
One month later, a follow-up 3g dose resulted in further enhancements in expressiveness and mobility. These changes were reported by her family and caregivers and marked a significant but temporary reversal of debilitating symptoms associated with her advanced Alzheimer’s disease.
Why it feels good
This case is exciting because it challenges long-held assumptions about the limits of brain function in neurodegenerative diseases like Alzheimer’s. Typically, the disease causes permanent neuronal damage, loss of memory, and reduced independence. However, the observed improvements suggest some brain functions might remain latent and accessible through altered neural communication.
Scientists are curious about how psilocybin may promote neuroplasticity—the brain’s ability to reorganize and form new connections. This compound impacts serotonin receptors linked to mood and cognition, which might temporarily boost communication among surviving brain networks. While the improvements are unlikely to reflect a true cure or reversal of damage, they point to new avenues for therapeutic research.
What to enjoy or watch next
Although this single case offers hope, it is important to remember the lack of controlled clinical trials to validate effectiveness or safety of psilocybin for Alzheimer’s patients. Researchers will continue to explore how psychedelic compounds interact with the brain’s plasticity and whether they can safely support cognitive function in neurodegenerative conditions.
For those interested in similar stories, books like Oliver Sacks’s 'Awakenings' depict comparable moments of regained abilities in largely incapacitated patients, highlighting the delicate balance between brain damage and hidden potential. Watching ongoing studies on psychedelics may reveal novel treatments that complement existing approaches to brain health and dementia care.